ticlopidine has been researched along with Fabry Disease in 1 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Fabry Disease: An X-linked inherited metabolic disease caused by a deficiency of lysosomal ALPHA-GALACTOSIDASE A. It is characterized by intralysosomal accumulation of globotriaosylceramide and other GLYCOSPHINGOLIPIDS in blood vessels throughout the body leading to multi-system complications including renal, cardiac, cerebrovascular, and skin disorders.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sakuraba, H | 1 |
| Igarashi, T | 1 |
| Shibata, T | 1 |
| Suzuki, Y | 1 |
1 other study available for ticlopidine and Fabry Disease
| Article | Year |
|---|---|
Effect of vitamin E and ticlopidine on platelet aggregation in Fabry's disease.
Topics: Adolescent; Adult; beta-Thromboglobulin; Child; Fabry Disease; Female; Heterozygote; Humans; In Vitr | 1987 |